$lfmd
Despite strong fundamentals and partnerships with major players like Eli Lilly and Novo Nordisk, $LFMD is experiencing significant underperformance relative to its partners, causing confusion in the market. Recent social posts highlight concerns about the stock's price action and its divergence from positive industry trends.
About $lfmd
$LFMD is a digital platform focused on user interaction and content sharing, particularly within the healthcare and telehealth sector.
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Month: [------] -74%
[--] Months: [---------] -69%
[--] Year: [---------] +66%
1-Year High: [-------] on 2025-11-17
1-Year Low: [---] on 2026-01-04
Engagements by network (24h): Reddit: [--] YouTube: [--] X: [-----]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-10-09
Mentions by network (24h): Reddit: [--] YouTube: [--] X: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $lfmd in the last [--] hours which is down 13% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-04-05
The most influential creators that mention $lfmd in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @ValueNotDeadYet | [--] | [-----] | [--] | [---] |
| @rynltmymy873300 | [--] | [--] | [--] | [---] |
| @TeleHInvesting | [--] | [---] | [--] | [--] |
| @ayasalmny | [--] | [--] | [--] | [--] |
| @CapitalVennett | [--] | [---] | [--] | [--] |
| @MarcJacksonLA | [--] | [-----] | [--] | [--] |
Sentiment: 75%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 75%
Daily Average: 78%
[--] Month: 60% -5%
[--] Months: 60% -9%
[--] Year: 60% -33%
1-Year High: 100% on 2025-02-19
1-Year Low: 6% on 2026-02-06
Most Supportive Themes:
- Strong Fundamentals and Partnerships: (50%) The company is highlighted for its strong financial metrics, including a low P/S ratio, high gross margin, significant cash reserves, and no debt, alongside strategic partnerships with major players like Eli Lilly ($LLY) and Novo Nordisk ($NVO).
- Industry Growth and Potential: (25%) The telehealth sector is experiencing significant CAGR, and the company is positioned to benefit from this growth, with expectations of positive stock performance driven by subscriber growth in oral GLP-1.
Most Critical Themes:
- Underperformance Relative to Partners: (50%) Despite strong sales from partners like Novo Nordisk ($NVO) for Wegovy, the company's stock is performing poorly, leading to confusion and questions about market dynamics.
Top $lfmd Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"@AbdullahAl12509 @TeleHInvesting No its sarcasm. $NVO Wegovy Oral is getting faster adoption than expected Ro is seeing very strong demand so this leads to a seemingly strong outlook for telehealth providers for this treatment yet $WW and $LFMD down massively past month"
X Link @ValueNotDeadYet 2026-02-16T04:36Z [----] followers, [---] engagements
"More bearish $LFMD read-through articles It was the fastest drug launch ever according to health analysts at Leerink Partners $NVO $LLY $WW $HIMS https://www.theguardian.com/science/2026/feb/15/weight-loss-race-injections-pills-big-pharma https://www.theguardian.com/science/2026/feb/15/weight-loss-race-injections-pills-big-pharma"
X Link @ValueNotDeadYet 2026-02-15T20:31Z [----] followers, [----] engagements
"$LFMD -5% total drawdown 91% converging into resistance"
X Link @apex_actuary 2026-02-11T02:19Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing